Presentation of abundant endogenous class II DR‐restricted antigens by DM‐negative B cell lines

Peptides derived from endogenous and exogenous antigens compete for binding and presentation via class II molecules. Studies with mutant B cell lines defective in exogenous antigen presentation suggest that HLA‐DM molecules facilitate the interaction of foreign peptides and class II molecules. In contrast, presentation of self antigens is not strictly dependent upon HLA‐DM, as demonstrated by the ability of these mutant cells to activate T cells specific for endogenous antigens. Two distinct classes of DM‐negative cells, T2 cells generated by in vitro mutagenesis and lines derived from bare lymphocyte syndrome (BLS) patients, were able to present epitopes derived from self proteins. Transfection of DM genes into the mutant cells enhanced the presentation of some, but not all, endogenous antigens, suggesting that formation of select endogenous peptide/class II complexes is not dependent upon DM. The efficiency of endogenous antigen presentation in the absence of DM was also dependent on the mutant antigen‐presenting cell studied, as the TxB hybrid T2 presented greater amounts of self peptides compared to cells from BLS patients. Thus, additional genes, aside from DM, may regulate the pathway for endogenous antigen presentation.

[1]  B. Mach,et al.  A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes , 1985, Nature.

[2]  F. Brodsky,et al.  Class II molecules of the major histocompatibility complex considered as differentiation markers. , 1986, Human immunology.

[3]  William Arbuthnot Sir Lane,et al.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.

[4]  H. Geuze,et al.  Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments , 1991, Nature.

[5]  S. Ceman,et al.  Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. , 1992, Science.

[6]  P. Gladstone,et al.  Identification of a trans-acting function regulating HLA-DR expression in a DR-negative B cell variant , 1980, Somatic cell genetics.

[7]  B. Evavold,et al.  Enhanced Dissociation of HLA-DR-Bound Peptides in the Presence of HLA-DM , 1996, Science.

[8]  D. Zaller,et al.  Mediation by HLA-DM of dissociation of peptides from HLA-DR , 1995, Nature.

[9]  N. Allbritton,et al.  Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced , 1996, The Journal of experimental medicine.

[10]  J. Trowsdale,et al.  Association between HLA-DM and HLA-DR in vivo. , 1996, Immunity.

[11]  Jeffrey A. Shaman,et al.  An essential role for HLA–DM in antigen presentation by class II major histocompatibility molecules , 1994, Nature.

[12]  P. Cresswell,et al.  Assembly, transport, and function of MHC class II molecules. , 1994, Annual review of immunology.

[13]  G. Loss,et al.  Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways , 1993, The Journal of experimental medicine.

[14]  A. Sant,et al.  Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules , 1996, The Journal of experimental medicine.

[15]  J. Gorski,et al.  Transcription analysis of class II human leukocyte antigen genes from normal and immunodeficient B lymphocytes, using polymerase chain reaction , 1990, Molecular and cellular biology.

[16]  P. Cresswell,et al.  In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. , 1994, Immunity.

[17]  P. Cresswell,et al.  Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding , 1990, Nature.

[18]  B. Durand,et al.  A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). , 1995, Genes & development.

[19]  R. Demars,et al.  Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. , 1984, Human immunology.

[20]  Eric O Long,et al.  Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. , 1993, Journal of immunology.

[21]  John Trowsdale,et al.  A new human HLA class II-related locus, DM , 1991, Nature.

[22]  G. Nepom,et al.  Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome , 1994, The Journal of experimental medicine.

[23]  P. L. Campbell,et al.  Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes. , 1994, Journal of immunology.

[24]  J. Rothbard,et al.  Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. , 1994, Journal of immunology.

[25]  A. Rudensky,et al.  Sequence analysis of peptides bound to MHC class II molecules , 1991, Nature.

[26]  M. Taylor,et al.  Endosomal aspartic proteinases are required for invariant-chain processing. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Nepom,et al.  Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome. , 1995, Journal of Clinical Investigation.

[28]  P. Cresswell,et al.  The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. , 1992, Journal of immunology.

[29]  B. Arp,et al.  Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes , 1990, Nature.

[30]  J. Trowsdale,et al.  Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. , 1994, Science.

[31]  Eric O Long,et al.  MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. , 1992, Journal of immunology.

[32]  P. Jensen,et al.  A structural transition in class II major histocompatibility complex proteins at mildly acidic pH , 1996, The Journal of experimental medicine.

[33]  G. Hämmerling,et al.  Editing of the HLA‐DR‐peptide repertoire by HLA‐DM. , 1996, The EMBO journal.

[34]  P. Cresswell,et al.  HLA-DM induces clip dissociation from MHC class II αβ dimers and facilitates peptide loading , 1995, Cell.

[35]  C. Seidl,et al.  Genetic complexity of regulatory mutants defective for HLA class II gene expression. , 1992, Journal of immunology.

[36]  A Sette,et al.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.

[37]  B. Mach,et al.  The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. , 1995, International immunology.

[38]  J. Trowsdale,et al.  Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs , 1996, The Journal of experimental medicine.

[39]  E. Bikoff.  Formation of complexes between self-peptides and MHC class II molecules in cells defective for presentation of exogenous protein antigens. , 1992, Journal of immunology.

[40]  S. Ceman,et al.  The function of invariant chain in class II-restricted antigen presentation. , 1995, Seminars in immunology.

[41]  J. Bonifacino,et al.  A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class II compartments , 1995, The Journal of cell biology.

[42]  B. Arp,et al.  HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells , 1994, Nature.

[43]  P. Cresswell,et al.  HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides , 1992, Nature.

[44]  A. Rudensky,et al.  Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line. , 1996, Journal of immunology.

[45]  R. Flavell,et al.  Class II transactivator regulates the expression of multiple genes involved in antigen presentation , 1995, The Journal of experimental medicine.

[46]  S. Ceman,et al.  DMA and DMB are the only genes in the class II region of the human MHC needed for class II-associated antigen processing. , 1995, Journal of immunology.

[47]  A. Rudensky,et al.  Intracellular assembly and transport of endogenous peptide-MHC class II complexes. , 1994, Immunity.

[48]  J. Blum,et al.  Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation. , 1997, Journal of immunology.

[49]  A Sette,et al.  Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II , 1995, The Journal of experimental medicine.

[50]  L. Lampson,et al.  Two populations of Ia-like molecules on a human B cell line. , 1980, Journal of immunology.

[51]  D. Weber,et al.  DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. , 1995, Immunity.

[52]  A. Woods,et al.  Human major histocompatibility complex class II-restricted T cell responses in transgenic mice , 1994, The Journal of experimental medicine.

[53]  P. Cresswell,et al.  Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.

[54]  C. Hume,et al.  Bare lymphocyte syndrome: altered HLA class II expression in B cell lines derived from two patients. , 1989, Human immunology.

[55]  P. Cresswell,et al.  Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. , 1994, Immunity.

[56]  A. Chervonsky,et al.  The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent , 1995, The Journal of experimental medicine.

[57]  G. Hämmerling,et al.  Self-Release of CLIP in Peptide Loading of HLA-DR Molecules , 1995, Science.

[58]  S. Diment,et al.  Selective processing of exogenous antigens by antigen-presenting cells with deleted MHC genes. , 1995, Journal of immunology.